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Peroxisome proliferator-activated receptors (PPARs)
have been suggested as the master regulators
of adipose tissue formation. However, their role in
regulating brown fat functionality has not been
resolved. To address this question, we generated
mice with inducible brown fat-specific deletions of
PPARa, b/d, and g, respectively. We found that
both PPARa and b/dd are dispensable for brown fat
function. In contrast, we could show that ablation of
PPARg in vitro and in vivo led to a reduced thermo-
genic capacity accompanied by a loss of inducibility
by b-adrenergic signaling, as well as a shift from
oxidative fatty acid metabolism to glucose utilization.
We identified glycerol kinase (Gyk) as a partial medi-
ator of PPARg function and could show that Gyk
expression correlates with brown fat thermogenic
capacity in human brown fat biopsies. Thus, Gyk
might constitute the link between PPARg-mediated
regulation of brown fat function and activation by
b-adrenergic signaling.
INTRODUCTION
Obesity is defined as abnormal fat accumulation and occurs due
to a long-term positive energy balance (Mittendorfer, 2011).
The global increase in obesity has been attributed to numerous760 Cell Reports 22, 760–773, January 16, 2018 ª 2017 The Author(s
This is an open access article under the CC BY-NC-ND license (http://factors including, but not limited to, altered food consumption
as well as a decrease in energy expenditure (Hill et al., 2012).
One possibility to induce energy expenditure is non-shivering
thermogenesis in brown adipose tissue (BAT). This process is
mediated by Uncoupling protein 1 (UCP1), which differentiates
BAT from classical white adipose tissue (WAT). Studies on the
regulation of BAT function have led to the identification of key
regulatory factors such as peroxisome proliferator-activated re-
ceptor g (PPARg), PGC1a, and PRDM16 (Ohno et al., 2012; Pet-
rovic et al., 2010). Particularly, PPARg2 is an important regulator
of both brown and white adipocyte differentiation (Barak et al.,
1999; Tontonoz et al., 1994). Recent evidence derived from the
analysis of post-translational modifications of PPARg have impli-
cated this factor not only as a regulator of adipocyte formation,
but also as a mediator of brown adipocyte functionality (Choi
et al., 2010; Hu et al., 1996; Qiang et al., 2012). Furthermore, it
was reported that Ucp1 mRNA abundance is higher in animals
treated with the PPARg agonist rosiglitazone (Festuccia et al.,
2010); however, whether this is due to a direct induction in
mature cells or due to de novo formation of brown adipocytes
is unknown. In human multipotent adipose-derived stem
(hMADS) cells, rosiglitazone-induced browning leads to
increased mitochondrial oxidative capacity, which is maintained
independently of rosiglitazone (Loft et al., 2015). In vivo studies
are complicated by the fact that global deletion of PPARg leads
to postnatal death at E10 (Barak et al., 1999). Thus, heterozy-
gous PPARg-deficient mice were shown to be protected from
age-induced insulin resistance, while studies using the aP2-
Cre to elicit an adipose tissue-specific knockout under
obesogenic conditions showed a reduction in weight gain and).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Loss of PPARg in IBA Reduces Brown-Adipocyte-Specific Marker Gene Expression and Leads to a Loss of Inducibility
(A) mRNA abundance of reverse transfected IBA with either non-targeting (siNT) or Pparg targeting (siPparg) siRNA showing Pparg1, Pparg2, Ucp1, Cidea, and
Ppara normalized to 36B4 (n = 4 per group; throughout, mRNA data are normalized to 36B4 and are expressed as mean ± SD; ***p < 0.001).
(B) Immunoblot of UCP1 and PPARg2 and 1 in IBA transfected with siNT or siPparg.
(C) Densiometric analysis of immunoblot (n = 3–4 per group; data are expressed as mean ± SD; **p% 0.01; ***p% 0.005).
(D) Mitochondrial stress test, showing OCR of IBA pre-treated with or without isoproterenol 1 hr (1 mM) before measurement (OCR-Data normalized to protein
content per well; n = 5).
(legend continued on next page)
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lipodystrophy (He et al., 2003; Jones et al., 2005). Interestingly, a
murine study using the aP2-CRE-ERT2 driver line to promote a
tamoxifen-dependent inducible knockout of PPARg demon-
strated a reduction of white and brown adipocyte survival (Imai
et al., 2004); however, given the drastic metabolic phenotype
of these animals, due to ablation of PPARg in white adipocytes,
it is unclear to what extent PPARg expression in BAT contributes
to the observed phenotype. While it is well accepted that PPARg
at least in part mediates mature brown adipocyte functionality,
surprisingly little data exist on downstream targets. It has been
previously shown that PPARg activates UCP1 expression by
binding to the UCP1 peroxisome proliferator response element
(PPRE) by nuclear translocation and binding of factors like reti-
noid X receptor (RXR) and PGC1a (Cao et al., 2004).
Here, we demonstrate that PPARg maintains thermogenic
function and the ability of BAT to be activated by b3-stimulation.
Using transcriptional analysis and loss- and gain-of-function
studies, we show that part of the effect of PPARg might be
mediated through the PPARg target glycerol kinase (GYK)
(Barquissau et al., 2016; Chakrabarty et al., 1983; Guan et al.,
2002; Mazzucotelli et al., 2007).
RESULTS
To analyze the role of PPARg in mature brown adipocytes and to
exclude the regulation of adipocyte differentiation, we utilized a
reverse transfection approach in fully differentiated, immortal-
ized brown adipocytes (IBAs). We obtained approximately
70% of knockdown for both Pparg1 and Pparg2 on both protein
and mRNA abundance (Figures 1A–1C), which led to a reduction
of brown adipocyte-specific transcripts such asUcp1 andCidea
as well as Ppara (Figure 1A). Similarly, we could show that loss of
PPARg expression led to an almost complete loss of UCP1
protein expression (Figures 1B and 1C). To elucidate whether
this effect was due to de-differentiation of the adipocytes, we
analyzed gene expression of brown and white mature and pre-
cursor markers. As shown in Figure S1A, we observed a varied
response; for example, the expression of the preadipocyte
marker Pref1was reduced, suggesting that knockdown of Pparg
does not lead to a dedifferentiation of themature adipocytes. In a
mitochondrial stress test, basal respiration of IBAs upon PPARg
ablation was not altered; however, loss of PPARg inhibited the
ability of IBAs to respond to b-adrenergic stimulation as a result
of reduced basal and leak respiration (Figures 1D and 1E). A
glucose stress test demonstrated that IBAs, upon PPARg
ablation, induced glycolysis as well as the glycolytic capacity
(Figures 1F and 1G). In line with these findings, we could show
that induction of UCP1 protein and mRNA expression in(E) Quantification of mitochondrial stress test (n = 5; data are expressed as mea
(F) Glucose stress test, showing OCR of IBA (n = 5).
(G) Quantification of glucose stress test (n = 5; data are expressed as mean ± SD
(H) Immunoblot of reverse transfected IBA with siNT or siPparg pre-treated 24
expression (n = 4).
(I) Immunoblot of phospho-PKA substrate in reverse transfected IBA with siNT o
(J) Immunoblot of reverse transfected IBA with siNT or siPparg showing phospho
(K) Free fatty acid (FFA) FFA release of IBA siNT and siPPARg treated at depicted
expressed as mean ± SD; **p% 0.01).
762 Cell Reports 22, 760–773, January 16, 2018response to a b-adrenergic stimulation was lost in IBAs with
suppressed PPARg expression (Figures 1H and S1B). The effect
was independent of global PKA activity (Figure 1I) and a more
detailed analysis of specific targets revealed that phosphory-
lated hormone sensitive lipase (pHSL) and HSL were mildly
reduced after PPARg ablation (Figure 1J). Furthermore, we
observed a significant reduction of activated cAMP response
element-binding protein (p-CREB) and an inability of cAMP to
stimulate Ucp1mRNA expression in the absence of PPARg (Fig-
ures S1C–S1E). Similarly, we could show, that PPARg ablation
led to a reduction in isoproterenol stimulated lipolysis (Figures
1K and S1F). Taken together, these findings demonstrate that
loss of PPARg in mature brown adipocytes reduces the capacity
to initiate the thermogenic program by b-adrenergic stimulation.
Since no functional studies analyzing the role of PPARg in
mature brown adipocytes exist, we generated an inducible
brown-fat-specific PPARg-deficient mouse model to deplete
PPARg exclusively in mature brown adipocytes (PPARg-
BATKO). Induced genetic ablation of PPARg led to a reduction
in Pparg mRNA expression (Figures 2A), a down-regulation of
Ucp1 mRNA and protein expression (Figures 2C and 2B) and
of other BAT markers such as Cidea and Cox7a1 (Figure 2C)
and Ppara. Conversely, we did not observe any reduction of
either Pparg or Ucp1 mRNA in iWAT (Figure S2E). Phenotypic
characterization of PPARg-BATKO mice showed neither a
weight phenotype nor any differences in body composition
(Figures 2D and S2A); however, we observed increased circu-
lating TAG, cholesterol, glucose, and non-esterified fatty acids
(NEFA) levels (Figures 2E–2G). PPARg-BATKO animals had
reduced BAT wet weight (Figure 2J) and histological analysis
of interscapular BAT depots revealed smaller adipocytes
containing less and/or smaller lipid droplets resulting in a higher
cell density (Figures 2H and 2I), without any changes in total cell
numbers. Last, pHSL, HSL, and the pHSL/HSL ratio were
reduced in BAT of PPARg-BATKO mice (Figures 2K and 2L).
Taken together, we could show that loss of PPARg in mature
brown adipocytes leads to a reduced systemic substrate
utilization, concomitant with a reduction in BAT marker gene
expression.
To investigate, whether PPARg ablation in BAT would alter
systemic respiration, PPARg-BATKO and littermate controls
were cold challenged for 7 days at 8C. Food and water intake
at room temperature was similar (Figure S3A), and, while in
cold, PPARg-BATKO mice exhibited elevated food and water
intake (Figure S3B). Even though core body temperature was
unaffected after a prolonged cold stimulus in these mice (Fig-
ure S2D), visual examination of the mice suggested an increased
shivering response, which together with alterations in food andn ± SD; a, b, c, d%0.05).
; *p% 0.05; **p% 0.01; ***p% 0.005).
hr with or without isoproterenol (1 mM) showing PPARg2 and 1 and UCP1
r siPparg pre-treated 24 hr with or without isoproterenol (1 mM) (n = 4).
r-HSL and gamma tubulin (n = 3).
time points, with or without isoproterenol (1 mM) pre-stimulation (n = 4; data are
Figure 2. Loss of PPARg In Vivo Reduces BAT Size and Thermogenic Gene Expression
(A) mRNA abundance of Ppara, Pparb/d, Pparg1, and Pparg2 normalized to 36B4 in BAT of WT, HET, and PPARg-BATKO animals (n = 6 WT versus 8 HET
versus 8 PPARg-BATKO; data are expressed as mean ± SD; a, b, c% 0.05).
(B) Immunoblot of UCP1 in PPARg-BATKO and WT animals and its respective densiometric quantification (n = 5 WT versus 4 PPARg-BATKO).
(C) mRNA abundance of brown fat marker genes Ucp1, Cidea, and Cox7a1 normalized to 36B4 (n = 6 WT versus 6 PPARg-BATKO; data are expressed as
mean ± SD; ***p% 0.005).
(D) Body mass development of PPARg-BATKO animals compared to Cre negative (WT) and Cre positive heterozygous littermates (HET) (n = 6 WT versus 8 HET
versus 10 PPARg-BATKO).
(E) Blood triglyceride and cholesterol of WT and PPARg-BATKO (n = 6 WT versus 8 PPARg-BATKO; data are expressed as mean ± SD; *p% 0.05).
(F) Blood glucose levels of WT and PPARg-BATKO (n = 6 WT versus 8 PPARg-BATKO; data are expressed as mean ± SD; *p% 0.05).
(G) Blood NEFA levels of WT and PPARg-BATKO (n = 6 WT versus 8 PPARg-BATKO).
(H and I) Cell density measurement of H&E-stained BAT paraffin sections (representative H&E stained BAT sections, H, and quantification, I) (n = 6 WT
versus 8 PPARg-BATKO; white scale bar, 100 mM).
(J) Tissue wet weight of WT and PPARg-BATKO (n = 5 WT versus 4 PPARg-BATKO; data are expressed as mean ± SD; ***p% 0.005).
(K) Immunoblot of lipolytic marker HSL and its phosphorylated form (n = 5 WT versus 4 PPARg-BATKO; data are expressed as mean ± SD; ***p% 0.005).
(L) Densiometric analysis of phosphorylated and unphosphorylated HSL of WT and PPARg-BATKO animals (n = 5 WT versus 4 PPARg-BATKO; data are
expressed as mean ± SD; *p% 0.05).
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water intake complicates the quantification of the contribution of
PPARg to energy expenditure (Figures S3C and S3D). Further-
more, the inability of the PPARg-BATKO mice to induce BAT
activity might affect the shivering response (Shefer and Talan,
1998), which in turn could confound the quantification of energy
expenditure. Therefore, we acutely treated PPARg-BATKO with
the b3-adrenergic receptor agonist CL316,243. Both PPARg-
BATKO and wild type mice showed similar rates of VO2 and
VCO2 at baseline (Figures 3A and 3B). UponCL316,243 injection,
PPARg-BATKO failed to induce respiration in the same manner
as wild-type (WT) animals (Figures 3D and 3E). This reduced
response in PPARg-BATKO resulted in a higher RER in
PPARg-BATKO (Figure 3C). To exclude any compensatory ef-
fects, we repeated the experiments at thermoneutrality, which
led to similar results (Figures 3D–3F). Taken together, those
data underline the importance of PPARg in maintaining brown
adipocyte functionality in response to b3-adrenergic receptor
activation.
Based on previous work, we hypothesized that PPARg
controls BAT functionality by regulating Ppara expression
(Barbera et al., 2001). In accordance, we could show that
depleting PPARa in mature IBAs by reverse transfection reduced
expression of brown adipocyte markersUcp1 andCidea both on
mRNA and on protein level (Figures 4A and 4B). To determine
whether PPARa was also responsible for maintaining BAT
function in vivo, we ablated PPARa specifically in BAT (PPARa-
BATKO). PPARa depletion in BAT did not affect classic BAT
marker expression, while bona fide PPARa markers were
reduced (Figures 4C and 4D). Food and water intake were unal-
tered at room temperature and during cold exposure (Figure 4E)
in PPARa-BATKO mice and we did not observe any changes in
VO2, VCO2, or RER (Figures 4F–4H). Similar to PPARa, expres-
sion of Pparb/d was dispensable for BAT function, in vivo as
demonstrated by the generation of PPARb/d-BATKO (Figures
S4A and S4B). Based on these data, we conclude that PPARa
plays a role in brown adipocyte function in vitro; however, both
PPARa and PPARb/d seem to be dispensable for mature brown
adipocyte functionality, in vivo.
To elucidate the pathway bywhich PPARg reduces the capac-
ity of BAT to be activated, we transcriptionally profiled the BAT of
3 days cold-challenged C57BL6/N animals and littermates at
room temperature (RT), as well as IBAs in the presence or
absence of PPARg. To identify direct brown adipocyte targets
of PPARg, we analyzed both the in vivo and in vitro comparison
for genes that bear PPRE, based on a published chromatin
immunoprecipitation (ChIP)-atlas (Nielsen et al., 2008). We found
231 regulated genes in PPARg-depleted IBAs and 168 genes in
cold-acclimatized mice (Figure 5A). An intersection of those two
lists resulted in 18 genes that were regulated in vitro and in vivo
and are classified as PPAR target genes (Table S1). Of these 18
genes, only Fabp3 andGyk, which has been previously identified
as a PPARg target in BAT (Guan et al., 2005), were enriched in
BAT. PPARg knockdown in IBAs led to a significant downregula-
tion of Gyk mRNA and protein expression both in the basal as
well as in the isoproterenol-induced state (Figures 5B, 5C, and
S5). In accordance with previous results (Festuccia et al.,
2010; Festuccia et al., 2003), we could show thatGyk expression
is elevated both in iBAT and iWAT after cold acclimatization764 Cell Reports 22, 760–773, January 16, 2018(Table S1; Figure 5D). Additionally, we observed an increased
GYK mRNA abundance in brown versus white differentiated
hMADs cells (Figure 5E). In human deep-neck biopsies, the
abundance of GYK correlated with UCP1, demonstrating that
GYK is a surrogate for BAT quantity and activity (Figure 5F).
Furthermore, positron emission tomography/computed tomog-
raphy (PET/CT)-guided biopsy of human supraclavicular BAT
showed higher brown adipocyte marker and GYK gene expres-
sion compared to WAT samples (Figure 5G). Taken together,
these results confirm that GYK is a direct target of PPARg in
brown adipocytes and that similar to UCP1 GYK is regulated
by cold induction in both mice and humans.
To test whether GYK ablation would result in a similar pheno-
type as a PPARg knockdown, we performed a small interfering
RNA (siRNA)-mediated knockdown of GYK in IBAs, which
resulted in an 80% reduction of GykmRNA and protein expres-
sion (Figures 6A, 6B, and S6C). Interestingly, GYK knockdown
led to a reduction of UCP1 protein expression (Figures 6B and
S6D) and pHSL levels under basal and stimulated conditions.
After GYK knockdown, isoproterenol treatment failed to
induce both GYK and UCP1 protein expression (Figures 6C,
S6C, and S6D), while we observed a slight induction of PPARg2
but not PPARg1 expression (Figures 6C, S6A, and S6B). GYK
knockdown did change adipocyte differentiation (Figures
S6G–S6I), and we were able to show that treatment of IBAs
with a competitive inhibitor of GYK (Seltzer et al., 1986) led to
a dose-dependent reduction in Ucp1 levels (Figure 6D). Rosigli-
tazone was unable to rescue BAT-specific gene expression in
GYK-ablated cells (Figure 6E), underscoring the importance of
GYK for maintaining mature brown adipocyte functionality.
Since GYK ablation in vivo causes lethality at P4 (Rahib et al.,
2007), we analyzed the role of GYK in BAT by local overexpres-
sion of Gyk through adenoviral-mediated gene delivery in both
WT and PPARg-BATKO mice. Re-expression of GYK did not
alter body weight and led to an approximately 2-fold induction
of GYK expression in iBAT of both WT and PPARg-BATKO
mice (Figures 6E and 6F), which is similar to the effect of a
cold stimulation. Similarly, we observed a 1.6-fold increase
in iBAT weight and 2.5-fold increase in total protein mass
when GYK expression was induced only in PPARg-BATKO
mice (Figures 6G and S6F). In general, overexpression of GYK
by adenovirus was able to restore the total levels of GYK to
approximately 50% of the WT control, and we observed a
similar increase of about 40% for total UCP1 levels. These
data demonstrate that GYK can modulate iBAT activity in vivo
and that the effect of PPARg ablation on UCP1 expression is
in part mediated through GYK. Similar to the results obtained
from PPARg knockdown, the respiration of IBAs upon GYK
siRNA-mediated knockdown were not changed (Figures 6H
and 6I); however, when stimulated by isoproterenol, Gyk
siRNA-treated cells showed reduced leak respiration. Interest-
ingly, we observed a slight increase in ATP production in Gyk
siRNA-treated cells under basal condition (Figures 6H and 6I),
and a glucose stress test showed that IBAs, upon GYK siRNA
knockdown, exhibit an increase in glycolysis (Figures 6J
and 6K). GYK generates glycerol-3-phosphate (G3P) from
glycerol (Robinson and Newsholme, 1969), which is required
to form lysophosphatidic acid (LPA) a key intermediate in TAG
Figure 3. Lack of PPARg in BAT Leads to a Reduced Response to Acute b3-Adrenergic Signaling
(A) VO2 at room temperature (RT) of WT and PPARg-BATKO with CL316,243 injection (1 mg/kg BM, i.p.) (n = 6 per group).
(B) VCO2 at RT of WT and PPARg-BATKO with or without CL316,243 injection (1 mg/kg BM, i.p.) (n = 6 per group).
(C) RER of 4 hr before and after CL316,243 injection of WT and PPARg-BATKO at RT (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD;
***p% 0.005).
(D) AUC analysis of VO2 at RT of WT and PPARg-BATKO after CL316,243 (CL) injection (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD;
*p% 0.05).
(E) AUC analysis of VCO2 at RT of WT and PPARg-BATKO after CL injection (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD).
(F) VO2 of WT and PPARg-BATKO with CL316,243 injection (1 mg/kg BM, i.p.) at 30
C (n = 6 per group).
(G) VCO2 of WT and PPARg-BATKO with or without CL316,243 injection (1 mg/kg BM, i.p.) at 30
C (n = 6 per group).
(H) RER of 4 hr before and 4 hr after CL316,243 injection ofWT and PPARg-BATKO at 30C (n = 6WT versus 6 PPARg-BATKO; data are expressed asmean ±SD;
***p% 0.005).
(I) AUC analysis of VO2 4 hr after CL316,243 injection ofWT and PPARg-BATKO (n = 6WT versus 6 PPARg-BATKO; data are expressed asmean ±SD; *p% 0.05).
(J) AUC analysis of VCO2 4 hr after CL316,243 injection of WT and PPARg-BATKO (n = 6 WT versus 6 PPARg-BATKO; data are expressed as mean ± SD;
*p% 0.05).
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Figure 4. Loss of PPARa Affects Mature Brown Adipocytes In Vitro but Not In Vivo
(A) mRNA abundance of reverse transfected IBA with non-targeting (siNT) or Ppara targeting (siPPARa) siRNA showing Ppara,Ucp1,Cidea, Pparg1, and Pparg2
normalized to 36B4 (n = 4 per group; data are expressed as mean ± SD; ** p% 0.01, ***p% 0.005).
(B) Immunoblot of reverse transfected IBA with siNT and siPPARa and the densiometric analysis of UCP1 to HSP90 (n = 4 per group; data are expressed as
mean ± SD; *p% 0.05).
(C) mRNA abundance of Ppara, Pparb/d, Pparg1, Pparg2, Cyp3a4, and Pltp in BAT of WT, HET, and PPARa-BATKO animals (n = 8 WT versus 7 HET versus 8
PPARa-BATKO).
(D) BAT marker mRNA abundance showing Ucp1, Cidea, and Cox7a1 (n = 8 WT versus 7 HET versus 8 PPARa-BATKO).
(E) Water and food intake of 24 hr in RT and in 4C of WT and PPARa-BATKO (n = 8 WT versus 7 PPARa-BATKO).
(F) VO2 in dark (gray background) and light phase each 12 hr at RT and 4
C of WT and PPARa-BATKO animals as well as AUC analysis (n = 8 WT versus 7
PPARa-BATKO).
(legend continued on next page)
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synthesis. As expected, both GYK and PPARg knockdown led
to a reduction of G3P in IBAs (Figure 6L) and GYK knockdown
led to a reduction of LPA and DAG levels (Figure 6M). Interest-
ingly, fatty acid CoA levels were higher in GYK-ablated cells,
suggesting that loss of PPARg and GYK leads to a reduced
capacity for TAG formation. To identify deregulated pathways,
we performed microarray analyses on IBAs with GYK ablation.
We could identify 124 downregulated and 142 upregulated
genes (Tables S4 and S5). Since several of these genes are
involved in the regulation of metabolism we performed a tran-
scription factor (TF) enrichment analysis, using the Metacore
platform. As shown in Figure 6N the top predicted TFs that
could explain the observed regulation were PPARa and PPARg,
suggesting a feedback loop for transcriptional regulation. In
conclusion, our data identify the PPARg/GYK axis as an impor-
tant node for the maintenance of mature brown function, which
is required for inducibility and the capacity to oxidize lipids in
response to brown adipocyte activation.
DISCUSSION
Our results show that PPARg is necessary to maintain BAT
thermogenesis and especially its inducibility by acute thiazolidi-
nediones (TZD), cAMP, or b-adrenergic stimuli in mature brown
adipocytes, in vitro and in vivo. We did not observe any changes
in PPARg and Ucp1 expression in the iWAT depot, which could
be due to the timing of the tamoxifen treatment. Since it has been
recently shown that the main Ucp1-dependent thermogenic
capacity in mice is located in classical BAT we focused our sub-
sequent studies on this particular tissue (Kalinovich et al., 2017).
Even though PPARa has an effect on brown adipocyte function
in vitro (Barbera et al., 2001) and pharmacological activation of
PPARa induces brown fat function (van Raalte et al., 2004),
we show here that neither PPARa nor PPARb/d are required
for mature BAT thermogenic functionality, in vivo. One possibility
for this finding might be that the loss of PPARa can be com-
pensated by PPARg to regulate brown adipocyte thermogenic
function.
Research data from pharmacological studies have identified
PPARg as an important regulator of BAT function. Thus, it is
possible to switch in an hMADs cell-culture system the pheno-
type of a ‘‘white like’’ adipocyte to an activated brown adipocyte
even though these cells do not respond to b-adrenergic stimula-
tion. Interestingly, we have recently shown that hMADs cells
before rosiglitazone treatment have a protein signature similar
to that of a brown adipocyte in the non-activated states
(M€uller et al., 2016). Therefore, it is possible that pharmacolog-
ical induction of PPARg can cause the activation of these cells,
although the mechanism is not yet known.
It has been shown that noradrenalin treatment leads to
the acute downregulation of PPARg expression and that its
expression is restored after 24 hr, which is in line with our find-(G) VCO2 in dark (gray background) and light phase each 12 hr at RT and 4
C o
PPARa-BATKO).
(H) RER in RT and 8C. mRNA data are normalized to 36B4; data are the mean
Student’s t test.ings presented here (Lindgren et al., 2004). Furthermore, it was
reported that mice treated with TZDs induce the amount of
BATs, without inducing beta-oxidation. This could be due to
negligible effects of brown fat induction, which is unlikely
given the strong reported effects of BAT ablation and Ucp1
knock out on the systemic metabolism (Feldmann et al., 2009).
A second option is that TZDs promote lipogenesis and dampen
the b-adrenergic-mediated activation of adipocytes in vivo, thus
masking BAT activation through other systemic alterations. Last,
based on the data reported here, it is possible that activation of
PPARg primes the brown adipocytes for induction. This is in line
with observations that TZD pre-treatment in cells significantly
enhances the inducibility by stimuli such as b-adrenergic activa-
tion (Hernandez et al., 2003, 2004).
From the results presented here, we propose that GYK is at
least in part required for mediating PPARg function in BAT and
thus constitutes a molecular link for maintenance of inducible
brown adipocyte thermogenesis. This is in line with previous re-
ports demonstrating that GYK is a direct PPARg target in brown
adipocytes (Guan et al., 2005). Next to UCP1, several marker
genes for brown adipocytes have been reported (Jespersen
et al., 2013; Sharp et al., 2012; Ussar et al., 2014). While GYK
is not a unique marker for brown tissue our data clearly indicate
that GYK is highly correlatedwith the amount of functional BAT in
humans, suggesting that it is required for brown adipocyte
thermogenic function. This is supported by the tissue-specific
expression of GYK in BAT and liver (Rahib et al., 2007; Robinson
and Newsholme, 1967) and the strong induction in WAT over
BAT expression coupled to the findings that showed that GYK
induction by thiazolidinedione stimulates glycerol incorporation
into triglycerides and reduces free fatty acid secretion from
adipocytes (Guan et al., 2002).
Based on our data, loss of PPARg leads to a reduced expres-
sion of GYK, thereby reducing the availability of the substrate
G3P for esterification of fatty acids, which leads to reduced
TAG synthesis and lipid storage. This in turn might lead to a
reduced capacity to sustain brown adipocyte function since
lipolysis is the main driver of thermogenesis (Haemmerle et al.,
2006) and in turn regulates PPARg activity in BAT. Based on
our data, it is furthermore possible that GYK similar to ATGL
(Haemmerle et al., 2011) is necessary to maintain the activity of
PPARs, which is supported by our observation that the expres-
sion of PPARa and PPARg target genes is reduced in the
absence of GYK. Given our data on the role of PPARa in mature
brown function, it is plausible that this effect is mainly due to the
regulation of PPARg. Even though multiple different lipids have
been suggested as PPARg ligands it is unlikely that the effect,
we observe is ligand dependent, as we were not able to rescue
GYK ablation through the addition of rosiglitazone. As it is well
established that PPARg activation is highly dependent on post-
transcriptional modifications (Ahmadian et al., 2013), it is
possible that GYK knockdown might activate a pathway, whichf WT and PPARa-BATKO animals as well as AUC analysis (n = 8 WT versus 7
± SD. *p < 0.05; ***p < 0.001; not significant (p > 0.05); by one or two-tailed
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Figure 5. Gyk Is a Target of PPARg in Human and Mouse Brown Adipocytes
(A) Analysis of Pparg in vitro chip microarrays and sequencing data of C57BL6/n in 3-day cold exposure at 8C.
(B) mRNA abundance of reverse transfected IBA with either siNT or siPPARg showing Pparg1, Pparg2, and Gyk normalized to 36B4 (n = 4 per group; data are
expressed as mean ± SD; ***p% 0.005).
(C) Immunoblot of reverse transfected IBA with either non-targeting (siNT) or PPARg targeting (siPPARg) siRNA showing GYK and its densiometric analysis
(n = 4 per group; data are expressed as mean ± SD; ***p% 0.005).
(D)Relative mRNA abundance of Ucp1 and Gyk in BAT and inguinal white adipose tissue (iWAT) of C57BL6/n at RT and 8C acclimatization for 7 days
(n = 5 RT versus 5 8C).
(E) Relative mRNA abundance of Ucp1 and Gyk of hMADS differentiated into white and brown adipocytes (n = 6 white versus 6 brown; data are expressed as
mean ± SD; *p% 0.05).
(F) Correlation of relative mRNA abundance of UCP1 and GYK in human deep-neck samples (n = 7).
(G) Relative mRNA abundance of UCP1, CIDEA, COX7A1, and GYK in PET-CT guided human brown and white adipose tissue of the supraclavicular area
(n = 7 white versus 7 brown; data are expressed as mean ± SD; ***p% 0.005). mRNA data are normalized to 36B4.cause a repression of PPARg activity, by a so-far unknown
post-transcriptional mechanism, independent of ligand-medi-
ated activation.768 Cell Reports 22, 760–773, January 16, 2018By overexpressing GYK in interscapular BAT, we could induce
thermogenic capacity, similar to an acute cold exposure. Taken
together with recent reports demonstrating an induction of
(legend on next page)
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Gyk expression upon cold stimulation (Festuccia et al., 2010;
Festuccia et al., 2003), it is likely that GYKmediates cold-induced
brown functionality in response to such a stimulus. In this context,
our data establish a link between cold induction and PPARg
activation that both induce brown fat functionality. Since TZD-
mediated induction of BAT mass and function and b3-receptor
activation of thermogenesis are two major regulatory nodes of
BAT, our data identify GYK as the link between these two path-
ways and thus serve as a target for inducing thermogenesis.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6N WT mice for experiments and breeding of transgenic lines were
obtained from Charles River Laboratories. The mouse strain containing a
floxed locus of PPARg (PPARgfl/fl) was created in the labs of Pierre Chambon
(Imai et al., 2004). PPARa and PPARb/d animals were provided byW.W. All an-
imals were kept on an inverted 12-hr-light cycle (beginning of dark phase at
7.00 a.m.), fed ad libitum chow diet. Animals were kept at 23C housing tem-
perature when not under cold stimulation. For tissue sampling, animals were
euthanized singly in a carbon dioxide atmosphere. Unless stated otherwise,
all experiments were performed with adult (11–14 weeks) male mice. Animals
used in the study all carried the UCP-ERCre allele (Rosenwald et al., 2013) and
the floxed PPAR allele as indicated. Tamoxifen induction of Cre activity was
performed as well in WT and knockout (KO) animals by gavaging the mice 4
times with 10 mg/mL per g body mass tamoxifen (Sigma) in sunflower oil
(Denner) when kept at 8C for 6 days. Experiments and further analysis were
performed 7 days after cold induction. All animal procedures were approved
by national and institutional guidelines.
Calorimetric Measurements
For measurements of respiratory quotient (respiratory exchange ratio, RER),
locomotor activity, food and water intake, a metabolic cage system was
used (Phenomaster, TSE Systems). Standard settings according to the
manufacturer’s instructions were used. Mice were fed ad libitum chow diet
andwater and consumption was determined during a full 24-hr-light cycle after
the animals could acclimatize to the cage and/or temperature for 24 hr.
Parameters were calculated to individual lean mass that were determined by
echo MRI. To generate b3-adrenergic stimulation, mice were intraperitoneally
(i.p.) injected with CL316,243 1 mg/kg BM.
Blood Parameters
Whole blood was sampled and adjusted to approximately 5 mM EDTA.
Samples were incubated for 10 min at RT and centrifuged 5 min 300 3 g.Figure 6. Gyk Is Involved in the Regulation of Brown Adipocyte Inducib
(A) mRNA abundance of reverse transfected IBA with siNT and glycerol kinase (siG
per group).
(B) Representative immunoblot of IBA with siNT or siGYK showing HSL, phosphor
(C) Immunoblot of IBA with siNT or siGyk with or without isoproterenol (1 mM) (n
(D) mRNA abundance of Ucp1 of IBA treated with 1-thiolglycerol at depicted con
(E) mRNA abundance of reverse transfected IBA with siNT and siGyk with or with
(F and G) Relative UCP1 protein and GYK abundance in (F) iBAT and (G) tissue we
adenoviral application into BAT with a 1 3 107 plaque-forming unit (PFU) adGF
PPARg-BATKO adGFP versus 7 PPARg-BATKO adGYKoe. Data are expressed
(H) OCR ratio of IBA siNT and siGYK from non- to isoproterenol (1 mM) stimulate
(I) Quantification of mitochondrial stress test (n = 5; data are expressed as mean
(J) Glucose stress test measurement, showing extracellular acidification rate (EC
(K) Respective quantification of Seahorse glucose stress test (n = 5; data are exp
(L) Measurement of glycerol-phosphates (Glycerol-P) in IBA treated either with s
(M) Lysophosphatidic acid (LPA), diacylglycerol (DAG), and fatty acid coenzyme A
or siGyk (n = 3 per group).
(N) TF enrichment analysis on microarray data frommock transfected iBAs versus
Metacore TF enrichment analysis of siGyk knockdown in IBA versus siNT contro
770 Cell Reports 22, 760–773, January 16, 2018Supernatant was flash-frozen in liquid nitrogen. Free fatty acid concentration
was determined with the NEFA-HR kit (Wako). To estimate triacylglycerol
and cholesterol concentration, Trig/GB andChol kits (both Roche) were. Blood
glucose levels were determined using Contour glucometers (Bayer).
Glucose Uptake
In IBAs, glucose uptake was performed on the second day after reverse
transfection with either non-targeting (NT) siRNA or Pparg siRNA. Cells were
incubated at 37C in Krebs Ringer buffer containing insulin, 2 mM glucose,
and C-deoxyglucose (200 cpm/mL). After 2 hr, cells were washed twice with
ice-cold PBS and lysed by one freeze thaw cycle in 2 M NaOH. Lysates
were mixed with 3 mL scintillation cocktail and intracellular radioactivity was
quantified in disintegrations per minute (dpm).
Paraffin Sections
Adipose tissues were excised, placed in embedding cassettes, and stored in
cold PBS. Samples were fixated in 4% paraformaldehyde (Sigma) in PBS
(Gibco) at RT. Processing was performed according to the standard protocol
in a STP 120 (Microm), and samples were embedded in paraffin and cut into
5-mm-thin sections on a Hyrax M55 (Zeiss). Sections were de-paraffinized
and stained with H&E on a Varistain 24-4 (Shandon) before mounting and
drying. Images were obtained with an Axioscope A.1 (Zeiss).
Cell Lines
Immortalized preadipocyte cell lines derived from the stromal-vascular fraction
of either interscapular BAT tissue of newborn or young mice were established
and provided by Dr. N. Perwitz and Prof. J. Klein (Universita¨t L€ubeck) according
to standard protocols (Klein et al., 2002; Perwitz et al., 2010). Cells were
cultured in high glucose (5 mM) DMEM containing 20% fetal calf serum
(FCS). All lines were maintained below confluency. To induce adipogenic
differentiation, the cell lines were grown to confluence on collagen-coated tis-
sue culture plates and maintained for 2 additional days. Immortalized brown
preadipocytes were induced by stimulation with 115 mg/mL IBMX, 1 mM dexa-
methasone, 20 nM insulin, 125 mM indomethacin, and 1 nM T3 in full medium.
After 24 hr, the medium was exchanged for full medium plus 20 nM insulin
and 1 nM T3. Cells were maintained in this medium until sampling for analysis.
To stimulate UCP1 expression for final read-out, the cells were incubated in full
medium with 1 mM isoproterenol for 8 hr before fixation or lysis.
For siRNA-mediated knockdown, Dharmacon smartPOOL on-target PLUS
RNA pools were used for reverse transfection. 25 nmol of siRNA were
incubated for 20 min in 0.25% Lipofectamine RNAiMAX in OptiMEM. Subse-
quently, they were mixed with cells in full growth medium and plated on
collagen-coated plates. siRNA-containing medium was replaced by full
growth medium 24 hr after lipofection. The sequences of the used siRNAs
are listed in Table S3.ility by PPARg
YK) targeting siRNA showing Gyk, Ucp1, and Cidea normalized to 36B4 (n = 4
ylated HSL, GYK, and UCP1, and densiometric quantification (n = 4 per group).
= 4 per group).
centrations (n = 4 per group).
out rosiglitazone (1 mM) normalized to 36B4 (n = 8 per group).
t weight of iWAT and iBAT of WT or PPARg-BATKO animals 10 days after local
P or adGYK adenovirus (n = 4 WT adGFPoe versus 5 WT adGYKoe versus 6
as mean ± SD; a, b, c p% 0.05).
d (OCR-Data normalized to protein content per well; n = 5).
± SD; a, b, c, d% 0.05).
AR) of IBA siNT and siGyk ± isoproterenol (1 mM).
ressed as mean ± SD; *p% 0.05; **p% 0.01; ***p% 0.005).
iNT, siPparg, or siGyk (n = 5–6 per group).
(FaCoA), normalized to phosphatidylserine (PS) of IBA treated with either siNT
iBAs after GYK ablation. Data are expressed as mean ± SD; a and b p% 0.05).
ls (p values are annotated; bars depict the inverted p value log to 10).
hMADS Cell Culture
The establishment and characterization of hMADS cells have been previously
described (Rodriguez et al., 2004). Cells were used between passages 14
and 25. Cells were seeded at a density of 5,000 cells/cm2 in DMEM
supplemented with 10% FBS, 15 mM HEPES, 2.5 ng/mL hFGF2, 60 mg/mL
penicillin, and 50 mg/mL streptomycin. hFGF2 was removed when cells
reached confluence. Cells were induced to differentiate at day 2 post-conflu-
ence (designated as day 0) in DMEM/Ham’s F12 media supplemented with
10 mg/mL transferrin, 10 nM insulin, 0.2 nM triiodothyronine, 1 mm dexameth-
asone, and 500 mm isobutyl-methylxanthine (IBMX). Two days later, the
medium was changed (dexamethasone and IBMX omitted) and 100 nM
rosiglitazone was added. At day 9, rosiglitazone was withdrawn to enable
white adipocyte differentiation but again included between days 14 and 18
to promote white to brite adipocyte conversion as we previously described
(Pisani et al., 2014). Media were changed every other day and cells were
used for analyses at day 18.
White BAT Biopsies from Patients
The clinical study for deep-neck biopsy was approved by the Local Ethics
Committee at the University Hospital in Bratislava, Slovakia, and it conforms
to the ethical guidelines of the 2000 Helsinki declaration. All study participants
provided witnessed written informed consent prior entering the study. Deep-
neck and adjacent subcutaneous adipose tissue samples were obtained
from the lower third of the neck by an experienced ear, nose, and throat
(ENT) surgeon from seven middle-aged (38.7 ± 3.1 years) non-obese (BMI
23.7 ± 0.4 kg/m2; waist circumference 82.1 ± 3.0 cm; body fat 28.7% ± 1.3
%) individuals (1M/6F) during neck surgery under general anesthesia (i.e.,
thyroid surgery [n = 6] or branchial cleft cyst surgery [n = 1]). The deep-neck
adipose tissue sample was taken from pre- and paravertebral space between
common carotid and trachea in case of thyroid surgery and just laterally to
carotid sheath in case of branchial cleft cyst surgery. In all cases, surgical
approach was sufficient to reach and sample the deep-neck adipose
tissue without any additional morbidity. Patients with malignant disease and
subjects younger than 18 years were excluded from participation in the study.
The PET/CT-guided human supraclavicular WAT and BAT samples were taken
as previously described (Orava et al., 2011).
Cellular Respiration
Differentiated cells were reverse transfected on rat collagen-coated 96-well
Seahorse cell-culture microplates. The oxygen consumption rate (OCR)
measurements were performed at 37C using an XF96 extracellular flux
analyzer (Seahorse Bioscience).
RNA Extraction, cDNA Synthesis, and Quantitative Real-Time PCR
Total RNA was extracted from tissues or unsorted cells using Trizol reagent
(Invitrogen). Final RNA samples were re-precipitated with NaOAc and ethanol
and washed with 70% ethanol before analysis on a Nanodrop-2000 spectro-
photometer. RNA from the human supraclavicular WAT and BAT samples
was isolated as previously described (Orava et al., 2011). Reverse transcription
was performed using the High Capacity cDNA Reverse transcription kit
(Applied Biosystems) with 20–2,000 ng of RNA for cell preparations or
whole-tissue preparations. qPCR was performed on a StepOnePlus (Applied
Biosystems), and relative mRNA concentrations normalized to the expression
of 36B4 were calculated by the DDCt method. qPCR primers and TaqMan
probes are listed in Table S2.
Microarrays
For microarray analyses, RNA preparations were checked for RNA integrity
and purity on Bioanalyser RNA nano chips. In case of adipocyte or SVF prep-
arations, 600 ng of total RNA per sample was labeled with the Microarray
Quick Amp Labelling Kit (Agilent) according to the manufacturer’s instructions.
RNA samples of whole adipose tissue were labeled as a service provided by
the Functional Genomics Centre Zurich (FGCZ). Hybridization to 4 3 44k
whole-mouse microarrays (Agilent) measurements and processing of raw
data were provided by the FGCZ. TF enrichment analysis was performed using
the Metacore platform.Western Blotting
Protein amounts were assessed using the DC Protein Assay (Bio-Rad).
Western blotting was carried out following standard procedures and
chemiluminescence signals were detected by an LAS 4000 mini ImageQuant
system (GE Healthcare). Primary antibodies used were as follows: UCP1
(1:1,000; ab10983 Abcam), HSL (1:1,000; #4107 Cell Signaling Technology),
p-HSL (Ser660, 1:1,000; #4126 Cell Signal), GAPDH (D16H11, 1:1,000;
#5174 Cell Signal), g-tubulin (1:1,000; T6557 Sigma), p-CREB (S133, 1:1000;
#9198 Cell Signal), CREB (1:1,000; #9197 Cell Signal), S6 ribosomal Protein
(1:1,000; #2217 Cell Signal), p-S6 ribosomal Protein (1:1,000; #5364 Cell
Signal), PPARg (1:1,000; #2443 Cell Signal), GYK (1:1,000; ab126599 Abcam),
and HSP90 (1:1,000; #4877 Cell Signal).
Metabolomics
IBAs were reverse transected in a 6-well plate with approximately 5 3 105
cells/well. Cells were left to attach for approximately 24 hr, followed by com-
plete medium removal, and washed with 13 PBS. Fresh medium was added,
and cells were incubated for further 24 hr. Sampling for metabolomics exper-
iment was performed as follows: the medium was removed, and cells were
washed twice with cold PBS and quenched by snap freezing the plate in liquid
N2. Plates were stored at –80C until proceeding with metabolite extraction.
The cold (–20C) extraction solution (acetonitrile/methanol/water [2:2:1]) was
used for metabolite extraction. 400 mL of cold extraction solution was added
to each well and incubated for 10 min at –20C. The supernatant was trans-
ferred to a tube and stored on ice. Then, the extraction was repeated by adding
additionally 400 mL of cold extraction solution followed by an incubation at
–20C. By keeping the plates on ice, cells were scraped and transferred to
the same tube used for the first extraction. Extracts were centrifuged
(4C, 13,000 rpm for 2 min), and the supernatants were transferred to fresh
tubes. Clean extracts were used for untargeted metabolomics, while superna-
tants were evaporated to complete dryness for targeted measurements.
For targeted metabolomics, the dried samples were resuspended in 100 mL
deionized water, and 15-mL aliquots were injected into a Waters Acquity
UPLC (Waters Corporation, Milford, MA) with a Waters Acquity T3 column
coupled to a Thermo TSQQuantumUltra triple quadrupole instrument (Thermo
Fisher Scientific) with negative-mode electrospray ionization. Compounds
were separated by a gradient of two mobile phases (A) 10 mM tributylamine,
15 mM acetic acid and 5% (v/v) methanol, and (B) 2-propanol. Acquisition of
mass isotopomer distributions of intact and fragmented carbon backbones
was done as previously described (R€uhl et al., 2012).
Statistical Analysis
Unless statedotherwise, data are presented asmean±SD.Unpaired and paired
two-sidedStudent’s t tests were used for comparisonswith *p < 0.05, **p < 0.01,
and ***p < 0.005 compared with control group. p > 0.05 are marked as not
significant or depicted with their exact p value. Area under the curve (AUC)
was calculated using the trapezoid method. Metabolomics data were analyzed
by using MATLAB R2015b and software developed in house. Student’s t test
distribution was used for calculating the significant changing metabolites
between different groups. Storey’s multiple testing correction was used for
p values to account for false discovery rate (Storey and Tibshirani, 2003).
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